Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006240 · ClinicalTrials.gov registry record · Phase 2
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
A Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006240: Completed Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00006240 is a Phase 2 study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006240, a Phase 2 study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining phenylbutyrate, dexamethasone, and sargramostim in treating patients who have refractory or relapsed acute myeloid leukemia.
Interventions
- DRUG dexamethasone
- BIOLOGICAL sargramostim
- DRUG oral sodium phenylbutyrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Est. Completion | 2001-08 |
| Phase | Phase 2 |
What the finished NCT00006240 record still lists
NCT00006240 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT00006240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006240 about?
NCT00006240 is a clinical study titled "Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from...
What is the current status of trial NCT00006240?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-10. Estimated completion is 2001-08.
What interventions are being tested in trial NCT00006240?
The interventions under investigation include: dexamethasone (DRUG), sargramostim (BIOLOGICAL), oral sodium phenylbutyrate (DRUG).
Who is sponsoring clinical trial NCT00006240?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia